Novo Nordisk to build new corporate centre in Bagsværd, Denmark

Novo NordiskNovo Nordisk is investing around 1 billion Danish kroner (134 million euros) in two new office buildings with surrounding green space in Bagsværd, Denmark. The project is expected to create more than 300 jobs during the construction phase. The new office premises will house Novo Nordisk's top management, 1,100 administrative employees and a number of shared facilities. Groundbreaking will take place in October, and the new corporate centre is expected to be ready for occupancy at the end of 2013.

With the new premises, Novo Nordisk will be consolidating a number of administrative functions currently scattered across Greater Copenhagen. In future, the employees will be gathered at new, contemporary offices at the Bagsværd and Søborg sites.

"Although Novo Nordisk is primarily set to grow outside of Denmark in the coming years, we are looking forward to consolidating the administrative functions in Bagsværd, where we have been present since the 1950s. The new buildings will give our employees the best conditions for interacting across functional divides and with our colleagues abroad," says Lars Rebien Sørensen, president and CEO of Novo Nordisk.

The insulin molecule with its contoured spiral shape was a key source of inspiration for Henning Larsen Architects. The new building will be distinctive in its white materials combined with Nordic stone and woods. The aim is to create a dynamic and inspiring work setting closely allied with external natural features, in an elegant, streamlined and efficient centre for Novo Nordisk.

Around 14,000 of Novo Nordisk's 32,000 employees work in Denmark. Beyond the Copenhagen area, Novo Nordisk has activities in Kalundborg, Hillerød, Værløse, Måløv and Hjørring.

About the building project

  • The new corporate centre will consist of two office buildings - a circular, six-storey building and a lower, four-storey building, underground parking and a large planted landscape.
  • Situated on a 37,000 m2 site, the new buildings will take up an area of 8,800 m2 with a total floorage of 50,500 m2.
  • The buildings will feature low energy consumption with the aid of sensors, light and ventilation, and will meet the 2015 energy requirements for new buildings.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]